Zepp Health Corporation

NYSE:ZEPP

Consumer Electronics

Technology
$3.55 -0.58%

-$0.03 today

Market cap
$50.84M
Beta
1.78
P/E (TTM)
-0.1
EPS (TTM)
-$282.07
52W Low $2.36High $61.85

Volume 0.04M

Average 0.13M

ZEPP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Zepp Health CorporationNYSE: ZEPP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was CN¥0, compared with CN¥89.89M a year earlier. Trailing-twelve-month research & development was CN¥234.24M. Over 3 fiscal years it compounded at -15.5% a year.

Context

  • Research & development amounted to 17.5% of revenue in FY2025, down 7.8 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near CN¥0 or moves back toward the trailing-twelve-month quarterly average of CN¥58.56M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CN¥0-100.0% QoQ
Last fiscal yearDec 2025
CN¥317.73M-5.7% YoY
LTMMar 2026
CN¥234.24M-27.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-5.7%——
3-year CAGR-15.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

CNY · from the income statement

Latest · FY2025
317.73M CNY
Year-over-year change
-5.7%
4-year CAGR
-11.1%

Research & Development vs competitors

How ZEPP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.9% is the 4th highest of 7, against a peer median of -21.8%.
  • Research & development amounts to 12.2% of revenue for ZEPP, versus a peer median of 16.1%.
ZEPP Competitors
Research & Development for ZEPP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZEPPZepp Health CorporationLTM Mar 2026CN¥234.24M CNY-27.9%-15.5%12.2%
SVCOSilvaco Group, Inc. Common StockLTM Mar 2026$33.82M USD+54.3%+33.9%50.7%
STEMStem, Inc.LTM Mar 2026$30.54M USD-37.0%-2.7%20.0%
EXFYExpensify, Inc.LTM Mar 2026$22.49M USD-6.6%+14.7%16.1%
KULRKULR Technology Group, Inc.LTM Mar 2026$10.08M USD+61.6%+36.9%54.3%
BWBabcock & Wilcox Enterprises, Inc.LTM Mar 2026$1.95M USD-61.5%-17.1%0.3%
TROOTROOPS, Inc.FY2025$0 USD——0.0%
TTECTTEC Holdings, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding ZEPP) —-21.8%+14.7%16.1%

Competitors are the stored peer set for ZEPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.17B4.22B2.5B1.33B1.82B
Cost of Revenue4.88B3.4B1.84B820.57M1.1B
Gross Profit1.29B817.22M653.7M512.88M711.63M
Gross Margin20.9%19.4%26.2%38.5%39.2%
Research & Development508.41M526.2M364.53M337.07M317.73M
Selling, General & Admin687.6M708.46M504.69M520.85M582.64M
Operating Expenses1.2B1.23B869.22M857.92M916.56M
Depreciation & Amortization51.21M59.65M54.43M36.64M31.71M
EBITDA200.8M(261.43M)(142.88M)(345.66M)(191.48M)
EBITDA Margin3.3%-6.2%-5.7%-25.9%-10.5%
Operating Income92.73M(417.45M)(215.52M)(345.04M)(204.93M)
Operating Margin1.5%-9.9%-8.6%-25.9%-11.3%
Interest Income16.47M12.55M21.86M26.81M10.7M
Interest Expense44.3M58M47.79M40.54M39.94M
Other Income / Expenses53.06M56.34M(21.7M)(108.55M)(58.2M)
Income Before Tax145.78M(361.11M)(237.22M)(453.59M)(263.13M)
Pre-Tax Margin2.4%-8.6%-9.5%-34.0%-14.5%
Income Tax Expense10.61M(67.03M)(17.2M)99.99M17.79M
Net Income136.02M(293.37M)(220.49M)(554.13M)(280.92M)
Net Margin2.2%-7.0%-8.8%-41.6%-15.5%
EPS (Basic)1.38(2.71)(1.96)(34.16)(283.04)
EPS (Diluted)1.31(2.71)(1.96)(34.16)(283.04)
Weighted Avg Shares15.76M15.39M15.2M16.18M993.87K
Weighted Avg Shares (Diluted)16.52M15.39M15.2M16.18M993.87K

Zepp Health Corporation

NYSE:ZEPP

Intrinsic Alpha fair value

Locked

Current Price

$3.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.